OMADA HEALTH INC (OMDA)
Health Care · Digital health and virtual chronic disease management · NASDAQ
Virtual care platform combining human health coaches and AI-driven technology to deliver preventive and chronic disease management programs for cardiometabolic conditions, obesity, and musculoskeletal health at scale.
What OMADA HEALTH INC does
Omada Health delivers virtual care programs combining human-led Care Teams (health coaches, specialists, physical therapists) with proprietary technology to address cardiometabolic conditions including diabetes prevention, diabetes management, hypertension, high cholesterol, as well as weight health, GLP-1 support, and musculoskeletal physical therapy. The company operates as a B2B2C platform, selling to employers, health plans, PBMs, health systems, and government entities who cover members. As of Q1 2026, Omada had over 1 million enrolled members and has supported nearly 2 million since launch, with strong engagement rates (55%+ in month 12 of cardiometabolic programs).
Themes: Cardiometabolic disease management, Diabetes prevention and management, Weight management / obesity, GLP-1 medication support, Virtual primary care, Digital health coaching, Chronic disease prevention, Hypertension management, Musculoskeletal / physical therapy, Behavioral health integration
Fundamentals
- Price$23.89 as of 2026-08-21 close
- Market cap$1.5B as of 2026-08-21
- 1-year return+11.3% 2025-08-21 close $21.46 → 2026-08-21 close $23.89
- P/En/a negative earnings
- Net margin-2.2% as of 2026-08-24
- Gross margin+66.3% as of 2026-08-24
- ROE-2.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+42.0% as of 2026-08-24
- Revenue CAGR (3y)+45.6% SEC XBRL
- Beta1.41 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How OMDA compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How OMADA HEALTH INC looks technically
OMADA HEALTH INC (OMDA) is trading 38.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 30 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day high about 10 trading days ago. Trading volume is unusually light — only about 33% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 38.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +38.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $21.51 | $21.51 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $17.27 | $17.27 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 25.17. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 30 trading days ago — a "golden cross", a bullish long-term signal | 30 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 30.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 58.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($18.61 to $25.17) — its "stochastic" reading is 80 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 80.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $26.91 | $26.91 |
|---|---|---|
| From the 52-week high | it is 11.2% below its 52-week high (its highest price of the past year) | -11.2% |
| Above the 52-week low | it is 132.4% above its 52-week low (its lowest price of the past year) | +132.4% |
| Below the 52-week high | it is 11.2% below its highest point of the past year | 11.2% |
| Since a 20-day breakout | it made a new 20-day high about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day high about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $28.40 (set on 2025-06-06) | $28.40 |
| Given back of the 52-week move | over the past year its closes ranged ($10.94 to $26.78), and it has recovered almost all of its fall from last year’s high — 82% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $20.73 to $21.24. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 81.8% |
| From the all-time high | it is 15.9% below its all-time high | -15.9% |
| Nearest price level | it is trading 2.0% below a resistance level at $24.38 — a price it turned at three times since 2025-09-08, most recently on 2026-07-16. Since 2025-06-06 it has 5 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.0% |
| All-time low | its lowest closing price on record is $10.28 (set on 2026-02-11) | $10.28 |
| Above the all-time low | it is 132.4% above its all-time low | +132.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.11 between its high and its low — about 4.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.11 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $18.03 and $26.37 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $18.03 – $22.20 – $26.37 |
| Typical daily range (% of price) | its price moves about 4.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.6% |
| Stretch from the 200-day average | it is trading 6.0 daily ranges above its 200-day average price (38.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 33% of its 30-day average | 0.33× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 5.9% since the prior reading | +5.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 6.0% above the previous close 10 sessions ago and has not traded back through the level it left behind at 19.54 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.0% |
| Gap filled | a 2.3% gap up opened on 2026-08-03 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.6 percentage points (the stock gained 3.9% while the market gained 2.3%) | +1.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 42.2 percentage points (the stock gained 45.3% while the market gained 3.1%) | +42.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 94.5 percentage points (the stock gained 105.6% while the market gained 11.1%) | +94.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 9.2 percentage points (the stock gained 11.3% while the market gained 20.5%) | -9.2% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 11.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +9.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 42% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $16.81 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | +42.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $23.58 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +1.3% |
Price levels it has turned at before
OMDA last closed at $23.89 on 2026-08-21. Since 2025-06-06 it has turned at 5 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $24.38 | Resistance | 2.0% above the last close | turned there three times · 2025-09-08 to 2026-07-16 |
| $21.16 | Support | 11.4% below the last close | turned there twice · 2025-08-08 to 2025-09-11 |
| $19.13 | Support | 19.9% below the last close | turned there twice · 2025-11-07 to 2025-12-02 |
| $16.59 | Support | 30.6% below the last close | turned there twice · 2025-08-01 to 2025-12-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $25.17.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 5 trading days, since 2026-08-17.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · At the top of its 14-day range (stochastic above 80) | Learn: moving average · golden cross · adx · rsi · macd · breakout · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.75 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$28.25 range $22.00 – $35.00; median $28.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OMDA
- Consensus EPS estimate$0.1026 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a limited number of customers and channel partners for substantial revenue; loss of major customers or channel partners could materially impact growth and profitability","Reliance on third-party channel partners (PBMs, health plans) who may reduce or discontinue partnerships, limiting end-customer access to Omada programs","Unprofitable operations with negative net margin (-2.22%); scaling to profitability requires continued revenue growth and operational efficiency improvements"]
What changed in the latest 10-Q
AI-assisted comparison of OMDA's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- As of March 31, 2026, we had over 1,025,000 total members enrolled in one or more programs, surpassing one million total members for the first time (newer filing, 2026-05-08)
- Reference to 'high cholesterol' added to list of cardiometabolic programs offered (newer filing, 2026-05-08)
- Description of prescribing capability incorporating third-party licensed obesity care providers for anti-obesity medications (AOMs) (newer filing, 2026-05-08)
- Reference to 'Cautionary Note Regarding Forward-Looking Statements' in risk disclosure (newer filing, 2026-05-08)
- Description of Care Teams composition including licensed physical therapists depending on program (newer filing, 2026-05-08)
- Reference to 'Between-Visit Care model' and Care Team Platform capabilities (newer filing, 2026-05-08)
- Statement that Omada has 'served over two million members since launch' (newer filing, 2026-05-08)
- Expanded description of integrated technology platform supporting entire lifecycle from benefit eligibility through billing infrastructure (newer filing, 2026-05-08)
- Reference to Medicare Advantage as a new channel with significant growth potential (newer filing, 2026-05-08)
- Removed:
- Description of delivering 'virtual care between doctor's visits' (older filing, 2025-11-07)
- Reference to 'Special Note Regarding Forward-Looking Statements' in risk disclosure (older filing, 2025-11-07)
- Statement that as of September 30, 2025, we had over 831,000 total members (older filing, 2025-11-07)
- Detailed explanation of member engagement metrics (interaction definitions such as logging in, sending messages, recording metrics) (older filing, 2025-11-07)
- Discussion of 'Our History' section with detailed program launch timeline and background (older filing, 2025-11-07)
- Detailed program descriptions for Prevention & Weight Health, Diabetes, and Hypertension programs (older filing, 2025-11-07)
- Reference to U.S. Preventive Services Task Force and CDC guidelines for Prevention & Weight Health program (older filing, 2025-11-07)
- Description of members being paired with dedicated health coaches and connected devices (older filing, 2025-11-07)
- Reference to Certified Diabetes Care and Education Specialists roles (older filing, 2025-11-07)
- Reworded:
- Changed from 'deliver virtual care between doctor's visits, providing an engaging, personalized, and integrated experience' to broader overview of mission and programs without this specific framing (2026-05-08 vs 2025-11-07)
- Changed from 'We work to develop trust with each member and use technology to help us personalize their experience' to 'Omada Care Teams are supported by our proprietary Care Team Platform' as primary technology narrative (2026-05-08 vs 2025-11-07)
- Changed from detailed explanation of customer types to broader statement about 'substantial opportunity to further grow our base of customers and channel partners' (2026-05-08 vs 2025-11-07)
- Shifted from program-specific details to higher-level 'Key Factors Affecting Our Performance' framework (2026-05-08 vs 2025-11-07)
- Notes:
- The older filing text provided appears truncated at the end (cuts off mid-sentence in Omada for Hypertension section), limiting full comparison of later MD&A content
- The newer filing excerpt also appears to end mid-sentence in the 'Investments in Growth' section, limiting complete comparison
- Comparison is limited to the portions of MD&A provided; full sections may contain additional changes not visible in truncated excerpts
Risk Factors
- Added:
- Added opening paragraph stating 'These disclosures reflect the Company's beliefs and opinions as to factors that could materially and adversely affect the Company and its securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past or their likelihood of occurring in the future.' (filed 2026-05-08)
- Added risk factor bullet point: 'Our programs may result in member harm or injury.' (filed 2026-05-08)
- Removed:
- Removed text at end: 'curtailment of our operations, any of which could materially and adversely affect our business, financial condition, results of operations, and prospects.' (filed 2025-11-07)
- Removed risk factor bullet point: 'Legislative or regulatory healthcare reforms or reductions in government spending may make it more difficult and costly to produce, market, and distribute our programs or to do so profitably.' (filed 2025-11-07)
- Removed text: 'We have identified material weaknesses in our internal control over financial reporting. If our remedia' (filed 2025-11-07)
- Reworded:
- Changed 'we may not achieve or maintain profitability' to 'we may not be able to consistently achieve or maintain profitability' in the net losses risk factor (filed 2026-05-08 vs 2025-11-07)
- Notes:
- The newer filing text is truncated at the end and does not include the complete final risk factor or any risk factors that may appear after the section shown
- The older filing text is also truncated and does not show complete content after the material weaknesses bullet point
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 52 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 8 sells ($1M) — 4 selling insiders
- Last 90 days0 buys · 52 sells ($8M) — 4 selling insiders
- Last 180 days0 buys · 52 sells ($8M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-12. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OMDA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding OMDA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 6,475,713
- Reported value $81,399,712
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
OMDA had 7,630,720 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
OMDA had 12.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.93 days to cover at the same settlement.
- Reported short interest (shares) 7,630,720
- Short interest (% of shares outstanding) 12.5%
- Prior settlement (shares) 7,980,607
- Reported change -4.38%
- Days to cover (reported) 5.93
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Livongo (Teladoc Health (TDOC))
- Hinge Health
- Virta Health
- WeightWatchers (WW)
- Noom
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OMDA vs…
Frequently asked questions
What does OMADA HEALTH INC (OMDA) do?
Omada Health delivers virtual care programs combining human-led Care Teams (health coaches, specialists, physical therapists) with proprietary technology to address cardiometabolic conditions including diabetes prevention, diabetes management, hypertension, high cholesterol, as well as weight health, GLP-1 support, and musculoskeletal physical therapy. The company operates as a B2B2C platform, selling to employers, health plans, PBMs, health systems, and government entities who cover members.
What sector is OMADA HEALTH INC (OMDA) in?
OMADA HEALTH INC (OMDA) is classified in the Health Care sector. Its industry is Digital health and virtual chronic disease management. It trades on NASDAQ.
Who are OMADA HEALTH INC's (OMDA) competitors?
Notable peers of OMADA HEALTH INC (OMDA) include Livongo (Teladoc Health (TDOC)), Hinge Health, Virta Health, WeightWatchers and Noom. This peer set is informational only — not financial advice.
Is OMADA HEALTH INC (OMDA) overbought or oversold right now?
OMADA HEALTH INC (OMDA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OMDA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.